Oruka Therapeutics

ORUKA THERAPEUTICS INC

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CHWY

HUMA

NYXH

ORKA

PPTA

RAPP

RGNX

ZYBT

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

GameStop Corp.

BHIL

BSGM

CISO

CLEU

GDHG

IMTE

PTPI

SURG

THTX

TXMD

WINT

Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

4 Stocks You Need To Buy Now for Consistent Profits—Here’s Why Analysts Love Them

Initiation

Analyst Ratings

CPRX

TRNO

VERA

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Oruka Therapeutics Inc

Press Releases

Oruka Therapeutics Announces $200 Million Private Placement

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Health Care

Oruka Therapeutics to Present at Multiple November Investor Conferences

Earnings

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to Present at Multiple March Investor Conferences

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Abivax

Akebia Therapeutics

Altimmune

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Celcuity

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Erasca

Keros Therapeutics

Kura Oncology

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Relay Therapeutics

Sage Therapeutics

Sana Biotechnology

Sionna Therapeutics

Stoke Therapeutics

Savara

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Tyra Biosciences

Verve Therapeutics

HC Wainwright & Co.

Wolfe Research

Stifel

Leerink Partners

Leerink Swann

Comments

Oruka Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga